Tumor mica status predicts the efficacy of immunotherapy with cytokine-induced killer cells for patients with gastric cancer

Table 1

Variable		N	m DFS	p-value	m OS	p-value
Sex	Male	66	42.0	0.373	44.0	0.229
	Female	29	42.0		50.0
Age	<65	67	41.0	0.588	48.0	0.464
	≥65	28	43.0		43.0
Histological grade	G1-G2	48	43.0	0.480	48.0	0.556
	G3-G4	47	31.0		43.0
Stage	II	44	50.0	0.001	51.0	0.006
	III	51	36.0		41.0
Adjuvant Chemotherapy	Xelox, Folfox4	57	41.0	0.250	43.0	0.257
	PF	38	42.0		46.0
CIK cycles	<5	54	40.0	0.046	42.0	0.075
	≥5	41	48.0		50.0
MICA status	High	38	46.0	0.027	48.0	0.031
	Low	57	41.0		42.0